These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 37672205)

  • 41. Single-Dose Focal Salvage High Dose Rate Brachytherapy for Locally Recurrent Prostate Cancer.
    Chitmanee P; Tsang Y; Tharmalingam H; Hamada M; Alonzi R; Ostler P; Hughes R; Lowe G; Hoskin P
    Clin Oncol (R Coll Radiol); 2020 Apr; 32(4):259-265. PubMed ID: 31708350
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Salvage Reirradiation for Locally Recurrent Prostate Cancer: Results From a Prospective Study With 7.2 Years of Follow-Up.
    Ekanger C; Helle SI; Reisæter L; Hysing LB; Kvåle R; Honoré A; Gravdal K; Pilskog S; Dahl O
    J Clin Oncol; 2024 Jun; 42(16):1934-1942. PubMed ID: 38652872
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Use of conformal high-dose rate brachytherapy for management of patients with prostate cancer: optimizing dose escalation.
    Vicini FA; Kestin LL; Martinez AA
    Tech Urol; 2000 Jun; 6(2):135-45. PubMed ID: 10798815
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Cancer of the Prostate Risk Assessment (CAPRA) score predicts biochemical recurrence in intermediate-risk prostate cancer treated with external beam radiotherapy (EBRT) dose escalation or low-dose rate (LDR) brachytherapy.
    Krishnan V; Delouya G; Bahary JP; Larrivée S; Taussky D
    BJU Int; 2014 Dec; 114(6):865-71. PubMed ID: 24274784
    [TBL] [Abstract][Full Text] [Related]  

  • 45. ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer.
    Rodda S; Tyldesley S; Morris WJ; Keyes M; Halperin R; Pai H; McKenzie M; Duncan G; Morton G; Hamm J; Murray N
    Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):286-295. PubMed ID: 28433432
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Preliminary toxicity and prostate-specific antigen response of a Phase I/II trial of neoadjuvant hormonal therapy, 103Pd brachytherapy, and three-dimensional conformal external beam irradiation in the treatment of locally advanced prostate cancer.
    Stock RG; Stone NN
    Brachytherapy; 2002; 1(1):2-10. PubMed ID: 15062181
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Salvage permanent perineal radioactive-seed implantation for treating recurrence of localized prostate adenocarcinoma after external beam radiotherapy.
    Aaronson DS; Yamasaki I; Gottschalk A; Speight J; Hsu IC; Pickett B; Roach M; Shinohara K
    BJU Int; 2009 Sep; 104(5):600-4. PubMed ID: 19245439
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Salvage robotic SBRT for local prostate cancer recurrence after radiotherapy: preliminary results of the Oscar Lambret Center.
    Leroy T; Lacornerie T; Bogart E; Nickers P; Lartigau E; Pasquier D
    Radiat Oncol; 2017 Jun; 12(1):95. PubMed ID: 28599663
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Salvage low-dose-rate brachytherapy for locally recurrent prostate cancer after definitive irradiation.
    Meraouna Y; Blanchard P; Losa S; Labib A; Krhili S; Pommier P; Crehange G; Flam T; Cosset JM; Kissel M
    Clin Transl Radiat Oncol; 2024 Sep; 48():100809. PubMed ID: 39027689
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Salvage low-dose-rate brachytherapy for prostate cancer local recurrence after radical prostatectomy: our first three patients.
    Gastaldi E; Gallo F; Chiono L; Giberti C
    Urologia; 2014; 81(1):46-50. PubMed ID: 24474541
    [TBL] [Abstract][Full Text] [Related]  

  • 52. High-dose-rate brachytherapy monotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer.
    Yamazaki H; Masui K; Suzuki G; Nakamura S; Yamada K; Okihara K; Shiraishi T; Yoshida K; Kotsuma T; Tanaka E; Otani K; Yoshioka Y; Ogawa K
    Radiother Oncol; 2019 Mar; 132():162-170. PubMed ID: 30416045
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Outcomes of salvage high dose-rate brachytherapy with or without pelvic external beam radiotherapy in patients with palpable local recurrence of prostate cancer after radical prostatectomy.
    Ni L; Chen K; Phuong C; Sabbagh AR; Wong AC; Mohamad O; Hsu IC
    Brachytherapy; 2023; 22(3):304-309. PubMed ID: 36623988
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Is supplemental external beam radiation therapy necessary for patients with higher risk prostate cancer treated with 103Pd? Results of two prospective randomized trials.
    Merrick GS; Wallner KE; Galbreath RW; Butler WM; Fiano R; Orio PF; Adamovich E
    Brachytherapy; 2015; 14(5):677-85. PubMed ID: 26051802
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer.
    Hiratsuka J; Jo Y; Yoshida K; Nagase N; Fujisawa M; Imajo Y
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):684-90. PubMed ID: 15183471
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-term outcomes analysis of low-dose-rate brachytherapy in clinically T3 high-risk prostate cancer.
    Agarwal M; Chhabra AM; Amin N; Braccioforte MH; Molitoris JK; Moran BJ
    Brachytherapy; 2018; 17(6):882-887. PubMed ID: 30143400
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A comparison of early prostate-specific antigen decline between prostate brachytherapy and different fractionation of external beam radiation-Impact on biochemical failure.
    Taussky D; Bedwani S; Meissner N; Bahary JP; Lambert C; Barkati M; Beauchemin MC; Ménard C; Delouya G
    Brachytherapy; 2018; 17(2):277-282. PubMed ID: 29306674
    [TBL] [Abstract][Full Text] [Related]  

  • 58. High-dose-rate brachytherapy plus external beam radiotherapy for T1 to T3 prostate cancer: an experience in Taiwan.
    Chen YC; Chuang CK; Hsieh ML; Chen WC; Fan KH; Yeh CY; Lee CC; Hong JH
    Urology; 2007 Jul; 70(1):101-5. PubMed ID: 17656217
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A Comparison Between Low-Dose-Rate Brachytherapy With or Without Androgen Deprivation, External Beam Radiation Therapy With or Without Androgen Deprivation, and Radical Prostatectomy With or Without Adjuvant or Salvage Radiation Therapy for High-Risk Prostate Cancer.
    Ciezki JP; Weller M; Reddy CA; Kittel J; Singh H; Tendulkar R; Stephans KL; Ulchaker J; Angermeier K; Stephenson A; Campbell S; Haber GP; Klein EA
    Int J Radiat Oncol Biol Phys; 2017 Apr; 97(5):962-975. PubMed ID: 28333019
    [TBL] [Abstract][Full Text] [Related]  

  • 60. High-dose-rate brachytherapy and external-beam radiotherapy for hormone-naïve low- and intermediate-risk prostate cancer: a 7-year experience.
    Aluwini S; van Rooij PH; Kirkels WJ; Jansen PP; Praag JO; Bangma CH; Kolkman-Deurloo IK
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1480-5. PubMed ID: 22285661
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.